AestheFill is a PDLLA (poly-D,L-lactic acid) collagen stimulator made by Regen Biotech. It is supplied as a lyophilized powder of PDLLA microparticles and carboxymethylcellulose, reconstituted before injection into the superficial subcutaneous layer. Rather than adding volume, the particles trigger a controlled inflammatory response that prompts the skin to build new collagen. Results vary by patient.
Key Takeaways
- AestheFill contains 154 mg PDLLA microparticles and 46 mg carboxymethylcellulose per the 2024 consensus paper.
- Its action is biostimulation: collagen is built over weeks, not delivered as immediate volume.
- Consensus guidance favors the superficial subcutaneous plane, a minimum 30-day session interval and careful reconstitution.
- Nodules and granulomas are the key complications to plan for; technique and product handling matter.
- Buyers should verify authenticity, cold-chain and documentation before stocking any biostimulator.
What Is AestheFill PDLLA and What Is in the Vial?
AestheFill is a PDLLA-based biostimulator marketed by Regen Biotech. According to the 2024 consensus paper by Magacho-Vieira et al. in Clinical, Cosmetic and Investigational Dermatology, each presentation contains 154 mg of microporous spherical PDLLA particles (average size 27 µm) and 46 mg of carboxymethylcellulose (CMC), supplied as a lyophilized powder in round pellets.
Other literature describes PDLLA microparticles in a 30-70 µm range: large enough to resist phagocytosis, small enough to pass through a needle. Sources differ slightly on size, which is a reminder to rely on the manufacturer's current product documentation for specifications. You can view the product listing for AestheFill PDLLA in our catalog.
How Does PDLLA Stimulate Collagen?
PDLLA stimulates collagen through a mild, controlled inflammatory response around the particles. The consensus paper reports myofibroblasts appearing among the microspheres by about week 2, extracellular type I collagen by week 4 and collagen synthesis within the particles by week 20.
A 2024 literature review in Polymers (Lee et al.) summarizes animal data suggesting PDLLA shifts macrophages toward an anti-inflammatory M2 phenotype, raises IL-10 and increases collagen types 1a1 and 3a1 in aged skin. The same review notes that the mechanism is still being elucidated and that excessive inflammation can cause granulomas and nodules. Practically, this means improvement is gradual and the treatment is not a substitute for volumizing filler.
How Is AestheFill Reconstituted and Injected?
The consensus recommendations describe reconstitution with 7 to 8 mL of sterile water for injection, followed by a 10 to 30 minute hydration period before agitation, and 1 to 2 mL of 2% lidocaine before injection. Final volume is typically 9 to 10 mL per vial for facial treatment and 10 to 20 mL for non-facial areas.
| Parameter | Consensus guidance (Magacho-Vieira et al., 2024) |
|---|---|
| Initial dilution | 7-8 mL sterile water for injection |
| Hydration before agitation | 10-30 minutes in the vial |
| Lidocaine 2% | 1-2 mL added before injection |
| Final volume (face) | 9-10 mL per vial |
| Preferred plane | Superficial subcutaneous |
| Techniques | Linear retrograde, fanning |
| Needle / cannula | 26-30 G needles; 22-25 G cannulas |
| Minimum session interval | 30 days |
The paper also describes a vacuum-assisted back-and-forth method using syringes and an 18-gauge needle that allows immediate reconstitution. Clinics should always follow the manufacturer's instructions for use and local regulations. For a comparable handling walkthrough of another biostimulator, see our guide to reconstituting Olidia PLLA.
How Many Sessions and How Often?
Consensus guidance sets a minimum of 30 days between sessions, with the final session at least 90 days after the penultimate one. Upkeep treatments are suggested around every 24 months, or annually in cases of accelerated collagen loss or advanced aging. Massage for the first 3 to 5 days is recommended though not essential. Individual plans depend on indication, and outcomes vary.
What Are the Risks and Complications?
Bruising, tenderness and edema are the common, usually mild effects. Nodules and granulomas are rarer but significant: nodules are attributed mainly to improper technique, granulomas to an exaggerated inflammatory response. The 2024 Polymers review also cites case reports of serious vascular events with PDLLA, which the authors link to possible air introduction during injection.
Prevention rests on correct plane, even distribution, adequate dilution and hydration, and practitioner training. For vascular emergency preparedness in a related category, see our filler vascular occlusion guide.
How Does PDLLA Compare With PLLA and PCL?
PDLLA, PLLA and PCL are all biostimulators but differ in polymer chemistry. The Polymers review, citing Chen et al. (2020), reports PDLLA has faster degradation and lower tensile strength than PLLA, with both biocompatible toward human skin fibroblasts. For a full side-by-side, read PLLA vs PCL vs PDLLA, or explore Olidia PLLA and Gouri liquid PCL.
What Should Buyers Check Before Stocking AestheFill?
Verify the supplier's documentation, batch traceability, packaging integrity and storage conditions before purchase. Our supplier documents checklist lists what to request, and regulatory status must be confirmed for your own country before import or use.
Frequently Asked Questions
What is AestheFill made of?
In the 2024 consensus paper, AestheFill (Regen Biotech) is described as a lyophilized powder containing 154 mg of poly-D,L-lactic acid (PDLLA) microporous spherical particles and 46 mg of carboxymethylcellulose (CMC). The particles stimulate collagen production through a controlled, subclinical inflammatory response rather than filling volume directly.
How is AestheFill reconstituted?
The consensus recommendations describe an initial dilution of 7 to 8 mL of sterile water for injection, a 10 to 30 minute hydration period in the vial before agitation, and 1 to 2 mL of 2% lidocaine added before injection. Always follow the manufacturer's instructions for use for your market.
How many sessions are typically recommended?
The consensus paper states a minimum interval of 30 days between sessions, with the last session at least 90 days after the penultimate one. Session numbers and maintenance timing depend on the indication and practitioner judgment, and results vary between patients.
What are the main risks of PDLLA injections?
Common effects are mild bruising, tenderness and edema. Nodules and granulomas are rarer but significant; nodules are mainly linked to improper technique and granulomas to exaggerated inflammatory responses. Rare vascular events have been reported in the literature for PDLLA, so practitioners must know the anatomy and emergency protocols.
How is PDLLA different from PLLA or PCL?
These are different polymers with different degradation profiles and handling. A 2024 literature review reports PDLLA degrades faster than PLLA, with lactic acid as its main degradation product, while PCL products such as Gouri use a different polymer altogether. Product choice depends on indication and clinic protocol.
Conclusion
AestheFill PDLLA is a biostimulator whose results depend on correct reconstitution, plane and patient selection. Clinics and distributors evaluating it can contact HolyPath for product and sourcing details.
References
- Magacho-Vieira FN et al. Consensus recommendations for the reconstitution and aesthetic use of PDLLA. Clin Cosmet Investig Dermatol. 2024;17:2755-2765
- Lee KWA et al. Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers. 2024;16(18):2583
This article is for informational purposes for licensed medical professionals and distributors. It is not medical advice. Treatments should be performed only by qualified practitioners in accordance with local regulations.